A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies

Cancer

Volumn 121, Issue 10, 2015, Pages 1645-1653

  Deeken, John F ^a   Wang, Hongkun ^b   Subramaniam, Deepa ^b   He, Aiwu Ruth ^b   Hwang, Jimmy ^c   Marshall, John L ^b   Urso, Christina E ^b   Wang, Yiru ^b   Ramos, Corinne ^d   Steadman, Kenneth ^b   Pishvaian, Michael J ^b  

^a Inova Comprehensive Cancer and Research Center   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c LEVINE CANCER INSTITUTE   (United States)

^d Theranostics Health Inc ^*  (United States)

Author keywords

cetuximab; clinical trial; epidermal growth factor receptor; lapatinib; phase 1; solid tumors; v erb b2 avian erythroblastic leukemia viral oncogene homolog 2

Indexed keywords

CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; STAT PROTEIN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; ADVANCED CANCER; ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PAIN; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SKIN MANIFESTATION; SOLID TUMOR; STOMATITIS; TREATMENT DURATION; TUMOR BIOPSY; VOMITING; AGED; ANUS NEOPLASMS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG ERUPTIONS; GENETIC VARIABILITY; GENETICS; GENOTYPE; HEAD AND NECK NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; COLORECTAL NEOPLASMS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; FEMALE; GENETIC VARIATION; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PHARMACOGENETICS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84929009007     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29224     Document Type: Conference Paper

References (35)

1. Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, et al. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol. 2014; 8: 1084-1094.
2. Cambridge DR, Pao W, Sequist LV,. Acquired resistance to TKIs in solid tumors: learning from lung cancer. Nat Rev Clin Oncol. 2014; 11: 473-481.
3. Erjala K, Sundvall M, Junttila TT, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2006; 12: 4103-4111.
4. Learn PA, Krishnegowda N, Talamantez J, et al. Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines. J Surg Res. 2006; 136: 227-231.
5. Rajput A, Koterba AP, Kreisberg JI, et al. A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo. Cancer Res. 2007; 67: 665-673.
6. Half E, Sun Y, Sinicrope FA,. Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. Cancer Lett. 2007; 251: 237-246.
7. Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008; 27: 3944-3956.
8. Kondo N, Ishiguro Y, Kimura M, et al. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncol Rep. 2008; 20: 373-378.
9. Kim HP, Han SW, Kim SH, et al. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol Cancer Ther. 2008; 7: 607-615.
10. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-345.
11. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359: 1116-1127.
12. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373: 1525-1531.
13. Lukan N, Ströbel P, Willer A, et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology. 2009; 77: 293-299.
14. Lacourture ME, Lacouture EP, Piperdi B, et al. Skin Toxicity Evaluation Protocol with Panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28: 1351-1357.
15. Von Hoff DD, Stephenson JJ, Rosen P, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010; 28: 4877-4883.
16. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005; 23: 5305-5313.
17. Weickhardt AJ, Price TJ, Chong G, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol. 2012; 30: 1505-1512.
18. Ramalingam S, Forster J, Naret C, et al. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monocloncal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. J Thorac Oncol. 2008; 3: 258-264.
19. Guarino MJ, Schneider CJ, Hosford MA, et al. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist. 2009; 14: 119-124.
20. Huang S, Armstrong EA, Benavente S, et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 2004; 64: 5355-5362.
21. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single agent receptor targeting. Clin Cancer Res. 2004; 10: 6487-6501.
22. Fields AL, Rinaldi DA, Henderson CA, et al. An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer [abstract]. J Clin Oncol. 2005; 23S. Abstract 3583.
23. de Souza JA, Davis DW, Zhang Y, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012; 18: 2336-2343.
24. Ross HJ, Blumenschein GR Jr, Aisner J, et al. Randomized phase II multicenter trial of 2 schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res. 2010; 16: 1938-1949.
25. Frank D, Jumonville A, Loconte NK, et al. A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: a Wisconsin Oncology Network study. J Gastrointest Oncol. 2012; 3: 90-96.
26. Dennie TW, Fleming RA, Bowen CJ, et al. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. Clin Colorectal Cancer. 2011; 10: 57-62.
27. Storniolo AM, Pegram MD, Overmoyer B, et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2008; 26: 3317-3323.
28. Greystoke A, Ranson M,. Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents. Ann Oncol. 2012; 23: 1934-1936.
29. Hamberg P, Verweij J,. Phase I drug combination trial design: walking the tightrope. J Clin Oncol. 2009; 27: 4441-4443.
30. Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab [serial online]. Sci Transl Med. 2011; 3: 99ra96.
31. Deeken J, Figg W, Bates SE, et al. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs. 2007; 18: 111-126.
32. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009; 27: 1122-1129.
33. Rodriguez J, Zarate R, Bandres E, et al. Fc gamma receptor polymorphisms as predictive markers of cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer. Eur J Cancer. 2012; 48: 1774-1780.
34. Sclafani F, Gonzalez de Castro D, Cunningham D, et al. FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease. Clin Cancer Res. 2014; 20: 4511-4519.
35. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol. 2010; 184: 512-520.